Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A small cell lung carcinoma detectable by sputum cytology only. The primary tumor is undetectable radiographically or during bronchoscopy; therefore, it can not be assessed.
Biomarker and diagnostic research for occult small cell lung carcinoma has been reported in the published literature.
No clinical trials have been registered for occult small cell lung carcinoma.
49 publications have been identified in PubMed for occult small cell lung carcinoma. Research spans Diagnostic / Biomarker (33%), Case Report / Case Series (22%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Testing and diagnosis research | 16 | 33% |
Data assembled from 2 of 12 sources · Last updated Oct 3, 2026, 1:41 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Patient case studies
11 |
22% |
Disease patterns and progression | 7 | 14% |
Clinical study results | 6 | 12% |
Research summaries | 5 | 10% |
Other research | 2 | 4% |
Laboratory research | 2 | 4% |
Huang Q (2026). [PMID: 41137928](https://pubmed.ncbi.nlm.nih.gov/41137928/). *Eur J Nucl Med Mol Imaging*. [Basic Science / Preclinical]
Bourbonne V (2026). [PMID: 41543547](https://pubmed.ncbi.nlm.nih.gov/41543547/). *Eur J Nucl Med Mol Imaging*. [Diagnostic / Biomarker]
Yesilcay HB (2026). [PMID: 42195199](https://pubmed.ncbi.nlm.nih.gov/42195199/). *Medicina (Kaunas)*. [Epidemiology / Natural History]
Desai PA (2026). [PMID: 41349181](https://pubmed.ncbi.nlm.nih.gov/41349181/). *Clin Lung Cancer*. [Review / Meta-Analysis]
Swamy N (2026). [PMID: 41835727](https://pubmed.ncbi.nlm.nih.gov/41835727/). *Cureus*. [Case Report / Case Series]
Tharwani A (2026). [PMID: 41846512](https://pubmed.ncbi.nlm.nih.gov/41846512/). *J Bronchology Interv Pulmonol*. [Epidemiology / Natural History]
Takemura C (2026). [PMID: 41177713](https://pubmed.ncbi.nlm.nih.gov/41177713/). *Clin Lung Cancer*. [Diagnostic / Biomarker]
Shen X (2026). [PMID: 40986090](https://pubmed.ncbi.nlm.nih.gov/40986090/). *Eur J Nucl Med Mol Imaging*. [Epidemiology / Natural History]
Abdallat M (2026). [PMID: 40784649](https://pubmed.ncbi.nlm.nih.gov/40784649/). *Ann Thorac Surg*. [Clinical Trial Publication]
Hu C (2026). [PMID: 41560074](https://pubmed.ncbi.nlm.nih.gov/41560074/). *Medicine (Baltimore)*. [Case Report / Case Series]
AI-curated news mentioning occult small cell lung carcinoma
Updated May 10, 2026
A case report highlights Pancoast syndrome and a middle ear mass as initial manifestations of small-cell lung carcinoma. This finding may enhance early detection strategies for this aggressive cancer.
FDA initiates real-time monitoring of cancer drug trials by AstraZeneca and Amgen to enhance efficiency in drug development. AstraZeneca's Phase 2 trial targets aggressive lymphoma, while Amgen's Phase 1b trial focuses on small cell lung carcinoma.